Ranibizumab is a humanized, affinity-matured vascular endothelial growth factor (VEGF) antibody fragment that neutralizes all isoforms of VEGF and is FDA approved for use in ophthalmology. Recently it was suggested that ranibizumab may be useful in the treatment of corneal neovascularization, but in reality this therapy is not yet evidence based.

中文翻译：

---

雷尼单抗在角膜新生血管形成中的治疗潜力

雷尼单抗是人源化的，亲和力成熟的血管内皮生长因子（VEGF）抗体片段，可中和VEGF的所有同工型，并已获得FDA批准用于眼科。最近有人提出，兰尼单抗可能在治疗角膜新生血管中有用，但实际上这种疗法尚无证据。